• Epidemiology
• inflammatory bowel disorders
• infliximab

In this intriguing article, Fidder et al report on the long-term follow-up of a cohort of subjects with inflammatory bowel disease (IBD) managed at a tertiary care institution.1 The authors conclude that IBD patients exposed to infliximab are at no higher risk for mortality or being diagnosed as having malignancy than controls with no prior infliximab exposure. These results would appear to confirm the safety of this drug in the treatment of IBD, as suggested by other studies of IBD cohorts followed over the long-term. However, it appears that this study may contain significant biases which …